Nadim Zaidan

Dr. Nadim Zaidan


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2022 in Toxins
Verified
Journal Article
Open access
PDF file
NZNadim Zaidan
Nadim Zaidan
LNLama Nazzal
Lama Nazzal
Uremic retention solutes, especially the protein-bound compounds, are toxic metabolites, difficult to eliminate with progressive renal functional decline. They are of particular interest because these uremic solutes are responsible for the pathogenesis of cardiovascular and chronic kidney diseases. Evidence suggests that the relation between uremic toxins, the microbiome, and its host is altered in patients with chronic kidney disease, with the colon’s motility, epithelial integrity, and absorptive properties also playing an important role. Studies found an alteration of the microbiota composition with differences in species proportion, diversity, and function. Since uremic toxins precursors are generated by the microbiota, multiple therapeutic options are currently being explored to address dysbiosis. While an oral adsorbent can decrease the transport of bacterial metabolites from the intestinal lumen to the blood, dietary measures, supplements (prebiotics, probiotics, and synbiotics), and antibiotics aim to target directly the gut microbiota composition. Innovative approaches, such as the modulation of bacterial enzymes, open new perspectives to decrease the plasma level of uremic toxins.

16 November 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RNRyan Njeim
Ryan Njeim
SPSai Shanmukha Sreeram Pannala
Sai Shanmukha Sreeram Pannala
NZNadim Zaidan
Nadim Zaidan
THToni Habib
Toni Habib
MRMedha Rajamanuri
Medha Rajamanuri
SESuzanne El-Sayegh
Suzanne El-Sayegh
Background: Patients with autoimmune diseases experience a higher burden of metabolic syndrome (MetS) and cardiovascular disease (CVD). There is a paucity of data regarding MetS in patients with inflammatory bowel disease (IBD) and its impact on CVD. In this retrospective study, we aimed to evaluate the prevalence of MetS components in IBD patients, as well as their association with acute coronary syndrome (ACS), heart failure and arrhythmias. Methods: After pooling 5 years of data from the National Inpatient Sample (NIS) Database (2016–2020), we compared traditional cardiovascular risk factors between IBD and non-IBD patients. We then investigated the association between MetS (represented by a calculated metabolic score (CMS) ranging from 0 to 4, based on the presence or absence of hypertension, obesity, dyslipidemia and type II diabetes) and CVD, separately for Crohn’s disease (CD) and ulcerative colitis (UC) patients. Results: The prevalence of the different MetS components was found to be lower in IBD patients compared to non-IBD patients. Comparing CD (n = 806,875) and UC (n = 575,925) identified a higher prevalence of MetS components in UC. Higher CMS was positively associated with ACS and arrhythmias in both CD and UC. This association was evident in heart failure, with the odds ratio increasing from 2.601 for CMS = 1 to 6.290 for CMS = 4 in UC patients and from 2.622 to 5.709 in CD patients. Conclusions: Our study highlights the positive association between traditional components of MetS and CVD in IBD patients. Our findings suggest that chronic inflammation explains only partially the CVD burden in hospitalized IBD patients.

1 June 2025 in American Journal of Physiology-Gastrointestinal and Liver Physiology
Verified
Journal Article
Closed access
KJKarim Jaber
Karim Jaber
NZNadim Zaidan
Nadim Zaidan
MHMelody Ho
Melody Ho
XXXiaozhong Xiong
Xiaozhong Xiong
RMRashmi Mishra
Rashmi Mishra
LNLama Nazzal
Lama Nazzal
This study is among the first to establish an enteric hyperoxaluria (EH) phenotype in two different and novel mouse models secondary to Roux-en-Y gastric bypass and ileitis. It also elucidates key factors affecting EH using the SAMP1 mice, revealing the significant roles of GI tract inflammation, fat malabsorption, and dietary fat in developing hyperoxaluria.

17 September 2025 in JGH Open
Verified
Journal Article
Open access
THToni Habib
Toni Habib
NZNadim Zaidan
Nadim Zaidan
KJKarim Jaber
Karim Jaber
HAHachem Araji
Hachem Araji
LDLiliane Deeb
Liliane Deeb
LNLama Nazzal
Lama Nazzal
Background: While many studies have identified steatotic liver disease (SLD) as a risk factor for kidney stone disease (KSD), the impact of the severity of steatosis has not been clearly elucidated in the context of other metabolic risk factors for KSD. This cross‐sectional population‐based study of a large inpatient database sought to investigate the association between KSD and SLD.Methods: We queried the National Inpatient Database between 2016 and 2020 to identify patients with urolithiasis as well as patients with SLD, and identify other risk factors for stone disease, such as obesity, type II diabetes, and gout using ICD10 codes. Logistic regression was computed for strength and significance of the relationship between both SLD severity levels and KSD, in univariate and multivariate regression adjusted for patient characteristics and comorbidities burden. All statistical analyses were performed using SAS Enterprise Software 9.4.Results: Odds of being a kidney stone former were significantly higher in patients with MASLD and MASH than in patients without liver injury in the general hospitalized population. Analysis performed in a cohort of hospitalizations that included BMI identifiers showed that this association of both degrees of SLD with KSD was more pronounced than that with diabetes and gout. Finally, comparing both forms of disease severity head‐to‐head, MASLD was found to have a stronger association with KSD than MASH.Conclusion: Patients with SLD were found to have a higher prevalence of KSD. The more pronounced association in MASLD and the lower‐than‐expected contribution of other conditions involving dysregulation of metabolic homeostasis such as gout or diabetes highlights the central role of SLD in KSD pathogenesis.

11 June 2025 in BJUI Compass
Verified
Journal Article
Open access
AKAnna Krieger
Anna Krieger
NZNadim Zaidan
Nadim Zaidan
PZPhilip Zhao
Philip Zhao
JBJames F. Borin
James F. Borin
DGDavid S. Goldfarb
David S. Goldfarb
Objectives: To review the different analgesic modalities and benefits of non‐opioid pain management options as well as their evidence‐based, established superiority, compared to opioid medications.Materials: We review the updated literature about pain management of renal colic, a prevalent and painful urologic condition. Prescribers must know the efficacy, safety and possible ramifications of analgesic selections.Results: Commonly prescribed medications in the United States (US) include non‐steroidal anti‐inflammatory drugs (NSAIDs), acetaminophen, and opioids. In the context of the current epidemic of death from overdoses of opioids in the US, the frequency of opioid prescribing for renal colic is likely excessive, problematic and potentially remediable. We also present analgesic modalities revolving around interventions with peri‐procedural pain management for ureteroscopy and percutaneous nephrolithotomy. After touching on the implications of misguided opioid use, especially in the context of kidney stone disease, and despite the evidence and consensus guidelines supporting NSAIDs in renal colic, current evidence has shown that many clinicians continue to prescribe opioids as first‐line treatment. Finally, we highlight current efforts targeted at the reduction of opioid use and prescription in the setting of provider education and decision aids in curbing misguided opioid use in renal colic.Conclusions: While the evidence against treating kidney stones with opioids is clear, more work is needed to shift current practices to reflect that renal colic is a non‐opioid‐requiring condition.

20 February 2026 in Medical Sciences
Verified
Journal Article
Open access
PDF file
AZAhmed Abdelmohsen Zayed
Ahmed Abdelmohsen Zayed
MKMichel El Khoury
Michel El Khoury
BABahy Abofrekha
Bahy Abofrekha
OAOluwakorede Akele
Oluwakorede Akele
HIHadi Itani
Hadi Itani
KSKevin Schesing
Kevin Schesing
Background: Traditional echocardiographic assessment of aortic stenosis (AS) using aortic valve area (AVA) may overestimate severity due to pressure recovery phenomena, while subclinical myocardial dysfunction remains undetected despite preserved ejection fraction. This study evaluated whether energy loss index (ELI)—which accounts for pressure recovery—demonstrates superior correlation with global longitudinal strain (GLS), a marker of subclinical myocardial dysfunction, compared to conventional AVA-based classification in patients with moderate-to-severe AS and preserved left ventricular ejection fraction (LVEF). Methods: This retrospective single-center study analyzed 149 patients with moderate-to-severe AS (AVA < 1.5 cm2) and LVEF > 50% from 2015 to 2019. Among 97 patients with severe AS by AVA (<1.0 cm2), ELI was calculated using the formula ELI = (AVA × Aa)/(Aa − AVA) ÷ BSA, where Aa represents sinotubular junction cross-sectional area. Patients with ELI ≥ 0.6 cm2/m2 were reclassified as moderate AS. Spearman correlation assessed relationships between AVA, ELI, and GLS. Multivariable linear regression models determined independent predictors of myocardial dysfunction, adjusting for age, body surface area, hypertension, LVEF, and mean pressure gradient. Results: ELI reclassified 28 of 97 patients (29%) from severe to moderate AS. Reclassified patients had significantly better myocardial function, with less impaired GLS (−15.0 ± 3.9% vs. −12.1 ± 5.0%, p = 0.013) and higher LVEF (60.1 ± 6.2% vs. 56.5 ± 9.1%, p = 0.017) compared to non-reclassified patients. In the overall cohort, ELI demonstrated stronger correlation with GLS than AVA (r = −0.307, p = 0.0003 vs. r = −0.209, p = 0.0115). Critically, among patients with severe AS by AVA criteria, ELI maintained significant correlation with GLS (r = −0.443, p = 0.0003) while AVA showed no correlation (r = −0.144, p = 0.159). In multivariable analysis, ELI independently predicted GLS (β = 5.847, 95% CI: 2.85–8.84, p = 0.0002; adjusted R2 = 0.289), whereas AVA did not (β = 2.234, 95% CI: −1.08 to 5.55, p = 0.188; adjusted R2 = 0.234). When both parameters were included simultaneously, only ELI remained significant (p = 0.0024). Conclusions: In this retrospective cohort, ELI-based reclassification identified a subgroup of patients with less severe myocardial dysfunction as measured by GLS and LVEF, and ELI demonstrated superior correlation with subclinical myocardial dysfunction compared to AVA. These findings suggest ELI may provide a more physiologically reflective assessment of hemodynamic burden in AS with preserved LVEF. However, the absence of systematic symptom assessment and clinical outcome data represents critical limitations. Prospective studies with standardized symptom evaluation, longitudinal follow-up, and adjudicated clinical endpoints are required to determine whether ELI-based reclassification improves risk stratification and clinical decision-making before this approach can be recommended for routine practice.